LC
TSHA icon

Lindbrook Capital’s Taysha Gene Therapies TSHA Stock Holding History

Lindbrook Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$605 Sell
435
-335
-44% -$560 ﹤0.01% 2589
2024
Q4 		$1.33K Buy
770
+546
+244% +$1.13K ﹤0.01% 2417
2024
Q3 		$450 Buy
+224
New +$491 ﹤0.01% 2698

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lindbrook Capital's TSHA Position: Q1 2025 in Review

Lindbrook Capital reduced its Taysha Gene Therapies (TSHA) stake by 44% in Q1 2025, selling an estimated $560 and leaving 435 shares worth $605. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Lindbrook Capital first reported a position in TSHA in Q3 2024 and has held it in 3 quarters since. The position peaked at $1.33K in Q4 2024. 127 funds tracked by Wall St. Rank hold TSHA as of Q1 2025.

  • Lindbrook Capital held 435 shares of Taysha Gene Therapies worth $605 as of Q1 2025.
  • Lindbrook Capital sold 335 Taysha Gene Therapies shares in Q1 2025, an estimated $560.
  • Taysha Gene Therapies made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2589 holding.
  • Lindbrook Capital first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 3 quarters since.
  • Lindbrook Capital's Taysha Gene Therapies position peaked at $1.33K in Q4 2024.
  • 127 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.